Beijing Hope Pharmaceutical Co., Ltd. is a high-tech pharmaceutical company based in China and facing the world. The main business is R&D, production and sales of APIs and APIs, import and export trade, R&D of new pharmaceutical preparations and new drug registration. We have an R&D center in Beijing, a pharmaceutical intermediate production base in Hebei and Zhejiang, and a GMP-certified API production base in Shandong.
*The following content is generated by AI and is for reference only.
Prasugrel Hydrochloride is a potent, third-generation thienopyridine antiplatelet agent widely utilized in clinical cardiology to prevent thrombotic cardiovascular events. Chemically known as Prasugrel HCl, its molecular formula is C18H25ClFNOS·HCl, and it bears the CAS Registry Number 360974-61-6. This compound functions as an irreversible inhibitor of the P2Y12 receptor on platelet surface membranes, thereby blocking adenosine diphosphate (ADP)-induced platelet activation and aggregation. Unlike its predecessors, clopidogrel and ticlopidine, Prasugrel HCl exhibits more rapid onset of action, greater potency, and more consistent pharmacodynamic effects due to its efficient metabolic conversion into a single active metabolite by hepatic cytochrome P450 enzymes.
The primary therapeutic application of Prasugrel HCl is in the management of acute coronary syndromes (ACS), specifically in patients undergoing percutaneous coronary intervention (PCI) with stent placement. It is frequently prescribed as part of dual antiplatelet therapy (DAPT) alongside aspirin to reduce the risk of fatal myocardial infarction, non-fatal stroke, or stent thrombosis. Clinical trials, such as the TRITON-TIMI 38 study, have demonstrated its superior efficacy compared to clopidogrel in reducing ischemic events, although this benefit must be carefully weighed against an increased risk of major bleeding. Consequently, its use is generally contraindicated in patients with a history of transient ischemic attack or stroke, as well as those with severe liver impairment or active pathological bleeding.
Pharmaceutically, Prasugrel HCl is supplied as white to off-white crystalline powder, highly soluble in water and organic solvents, facilitating various dosage forms including tablets for oral administration. Its stability profile allows for reliable storage under standard conditions, ensuring consistent drug delivery. As a critical component in modern interventional cardiology, Prasugrel HCl represents a significant advancement in antithrombotic therapy, offering clinicians a robust tool to manage high-risk coronary artery disease while requiring vigilant monitoring of bleeding complications. Ongoing research continues to explore optimal dosing strategies and patient selection criteria to maximize therapeutic benefits while minimizing adverse outcomes in diverse populations.